These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2668647)

  • 1. Treatment of RAEB-t with intensive chemotherapy and GM-CSF.
    Brito-Babapulle F; Lord JA; Whitmore DN
    Leuk Res; 1989; 13(7):605-7. PubMed ID: 2668647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study.
    Bennett JM; Young MS; Liesveld JL; Paietta E; Miller KB; Lazarus HM; Marsh RD; Friedenberg WR; Saba HT; Hayes FA; Dewald GW; Hiddemann W; Rowe JM
    Am J Hematol; 2001 Jan; 66(1):23-7. PubMed ID: 11426487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.
    Gerhartz HH; Marcus R; Delmer A; Zwierzina H; de Witte T; Jacobs A; Visiani G; Fiere D; Sonneveld P; Labar B
    Infection; 1992; 20 Suppl 2():S116-23. PubMed ID: 1493935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t.
    Creutzig U; Bender-Götze C; Ritter J; Zimmermann M; Stollmann-Gibbels B; Körholz D; Niemeyer C
    Leukemia; 1998 May; 12(5):652-9. PubMed ID: 9593261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.
    Thompson JA; Lee DJ; Kidd P; Rubin E; Kaufmann J; Bonnem EM; Fefer A
    J Clin Oncol; 1989 May; 7(5):629-37. PubMed ID: 2651578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study.
    Kikuchi A; Hasegawa D; Ohtsuka Y; Hamamoto K; Kojima S; Okamura J; Nakahata T; Manabe A;
    Br J Haematol; 2012 Sep; 158(5):657-61. PubMed ID: 22734597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study.
    Ho AD; Del Valle F; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Haas R; Thiel E; Andreesen R; Fiedler W
    Cancer; 1990 Aug; 66(3):423-30. PubMed ID: 2194641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study.
    Höffken K; Overkamp F; Stirbu J; Grothey A; Flasshove M; Hoelzer D; Ganser A
    Onkologie; 1990 Feb; 13(1):33-7. PubMed ID: 2186322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combined GM-CSF and erythropoietin therapy in myelodysplastic syndrome].
    Egli F; Hofer S; Greminger P; Rhyner K
    Schweiz Med Wochenschr; 1989 Dec; 119(49):1777-80. PubMed ID: 2694367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.
    Jackson G; Taylor P; Smith GM; Marcus R; Smith A; Chu P; Littlewood TJ; Duncombe A; Hutchinson M; Mehta AB; Johnson SA; Carey P; MacKie MJ; Ganly PS; Turner GE; Deane M; Schey S; Brookes J; Tollerfield SM; Wilson MP
    Br J Haematol; 2001 Jan; 112(1):127-37. PubMed ID: 11167793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine arabinoside in patients with myelodysplastic syndrome. A pilot study.
    Ganser A; Ottmann OG; Schulz G; Hoelzer D
    Onkologie; 1989 Feb; 12(1):13-5. PubMed ID: 2654786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of recombinant G-CSF and GM-CSF on in vitro differentiation of the blast cells of RAEB and RAEB-T.
    Tohyama K; Ohmori S; Michishita M; Ueda T; Ueda Y; Sakoda H; Yoshida Y; Uchino H
    Eur J Haematol; 1989 Apr; 42(4):348-53. PubMed ID: 2470613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked and reproducible increase in trilineage blood cell counts by administration of granulocyte colony-stimulating factor in a patient with refractory anaemia with excess blasts in transformation.
    Chiba S; Inamori K; Mitani K; Hirai H; Yazaki Y
    Br J Haematol; 1994 Mar; 86(3):665-7. PubMed ID: 7519041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes.
    Delforge M; Demuynck H; Vandenberghe P; Verhoef G; Zachée P; van Duppen V; Marijnen P; Van den Berghe H; Boogaerts MA
    Blood; 1995 Nov; 86(10):3660-7. PubMed ID: 7579331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing response of clonogenic myeloid leukemia blasts to granulocyte-macrophage colony-stimulating factor (GM-CSF) during anti-leukemic therapy--a case report on the basis of a clinical phase II trial.
    Hiddemann W; Zühlsdorf M; Wörmann B; Koenigsmann M; Büchner T
    Leuk Res; 1990; 14(4):347-52. PubMed ID: 2185381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low dose cytosine arabinoside in refractory anemia with excess of blasts in transformation.
    Fridrik MA; Wahl G; Herbinger W
    Blut; 1988 Dec; 57(6):357-60. PubMed ID: 3207893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GM-CSF treatment in aplasia after cytotoxic therapy.
    Gattringer C; Thaler J; Drach J; Micksche M; Huber H
    Onkologie; 1989 Feb; 12(1):16-8. PubMed ID: 2654787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A combination chemotherapy with cytarabine ocfosfate, low dose etoposide, and G-CSF for the treatment of high risk MDS (RAEB, RAEBt)--a pilot study].
    Hara M; Kojima K; Azuma T; Narumi H; Shinagawa K
    Rinsho Ketsueki; 1998 Apr; 39(4):314-6. PubMed ID: 9597900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
    Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
    Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.